Rocket Pharmaceuticals in-27RCKTWPreferred / convertible
13F holders, Q1 2026 (March 31)10holders −2
1new positions
3sold out
1famous investor
$0.10avg. 13F price*
At the end of Q1 2026, 10 institutions reported holding Rocket Pharmaceuticals in-27 (RCKTW) in their 13F filings, down 2 from Q4 2025. 1 opened new positions and 3 sold out. The largest holders were Boothbay Fund Management, LLC ($132K), RTW Investments, LP ($7K) and Sio Capital Management, LLC ($7K). One famous investor held it Ken Griffin ( of Citadel Advisors's portfolio).
- Company
- Rocket Pharmaceuticals in-27
- CUSIP
- 77313F114
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $84 |
| Exits | 3 | $403 |
All 13F filers, Q4 2025 → Q1 2026: 3,981 shares bought and 36,838 shares sold, net −32,857 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 10 holders
| Boothbay Fund Management, LLC | — | No change | 36,912 | $132K |
| RTW Investments, LP | — | No change | 350,000 | $7K |
| Sio Capital Management, LLC | — | No change | 400,000 | $7K |
| Citadel Advisors | — | Reduce -0.5% | 309,997 | $7K |
| Walleye Capital LLC | — | No change | 284,345 | $6K |
| Silverarc Capital Management, LLC | — | No change | 104,828 | $2K |
| LMR Partners LLP | — | No change | 75,731 | $2K |
| Affinity Asset Advisors, LLC | — | No change | 75,000 | $1K |
| Ancora Advisors LLC | — | No change | 6,000 | $124 |
| UBS Group AG | — | New | 3,981 | $84 |
"% of holder's portfolio" is RCKTW's weight in each manager's 13F, not the share of Rocket Pharmaceuticals in-27 the manager owns.